HNF1B变异与17q12微缺失患者的肾脏及肾外表型
这项回顾性观察研究纳入14国521例HNF1B病患,比较17q12缺失与HNF1B变异者的肾脏生存。中位随访11年,17q12缺失者进展至CKD3期风险显著低于变异者(HR 0.29)。POUs DNA结合域变异者肾脏生存最差。
要点
- 17q12缺失者进展至CKD3期风险低于HNF1B变异者(HR 0.29)。
- POUs DNA结合域变异者肾脏生存最差。
- 17q12缺失与低镁血症正相关,与高尿酸血症负相关。
核心结论
- 17q12缺失患者肾脏生存显著优于其他HNF1B变异患者。
- POUs DNA结合域变异导致最差的肾脏生存。
研究设计与样本
- 回顾性观察研究,纳入14国521例HNF1B病患者,中位随访11年。
主要发现
- 17q12缺失者进展至CKD3期风险显著低于HNF1B变异者(HR 0.29,95%CI 0.19-0.44,P<0.001)。
- POUh域变异者进展至CKD3期风险显著低于POUs域变异者(HR 0.15,95%CI 0.06-0.37,P<0.001)。
- POUs域变异者进展风险亦低于POUs域变异者(HR 0.25,95%CI 0.11-0.57,P=0.001)。
- 17q12缺失与低镁血症正相关,与高尿酸血症负相关,与高血糖无关。
关键数值与推荐
- 主要终点为进展至CKD3期(eGFR<60 ml/min per 1.73 m2)。
临床怎么用
- HNF1B基因型可帮助预测肾脏预后并指导遗传咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hepatocyte nuclear factor 1-beta (HNF1B) gene variants or the chromosome 17q12 deletion (17q12del) represent the most common monogenic cause of developmental kidney disease. Although neurodevelopmental disorders have been associated with the 17q12del, specific genotype-phenotype associations with respect to kidney function evolution have not yet been fully defined. Here, we aimed to determine whether 17q12del or specific HNF1B variants were associated with kidney survival in a large patient population with HNF1B disease. METHODS: This was a retrospective observational study involving 521 patients with HNF1B disease from 14 countries using the European Reference Network for rare kidney diseases with detailed information on the HNF1B genotype (HNF1B variants or the 17q12del). Median follow-up time was 11 years with 6 visits per patient. The primary end point was progression to chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m2). Secondary end points were the development of hypomagnesemia or extrarenal disorders, including hyperuricemia and hyperglycemia. RESULTS: Progression toward CKD stage 3 was significantly delayed in patients with the 17q12del compared to patients with HNF1B variants (hazard ratio [HR]: 0.29, 95% confidence interval [CI]: 0.19-0.44, P < 0.001). Progression toward CKD stage 3 was also significantly delayed when HNF1B variants involved the HNF1B Pit-1, Oct-1, and Unc-86 homeodomain (POUh) DNA-binding and transactivation domains rather than the POU-specific domain (POUs) DNA-binding domain (HR: 0.15 [95% CI: 0.06-0.37), P < 0.001 and HR: 0.25 (95% CI: 0.11-0.57), P = 0.001, respectively). Finally, the 17q12del was positively associated with hypomagnesemia and negatively associated with hyperuricemia, but not with hyperglycemia. CONCLUSION: Patients with the 17q12del display a significantly better kidney survival than patients with other HNF1B variants; and for the latter, variants in the POUs DNA-binding domain lead to the poorest kidney survival. These are clinically relevant HNF1B kidney genotype-phenotype correlations that inform genetic counseling.
引用
- Buffin-Meyer B, Richard J, Guigonis V, et al. Renal and Extrarenal Phenotypes in Patients With HNF1B Variants and Chromosome 17q12 Microdeletions. Kidney Int Rep. 2024. PMID: 39156164. doi:10.1016/j.ekir.2024.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。